Fulgent Genetics

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fulgent Genetics surpasses revenue targets, eyes precision medicine growth

Fulgent Genetics delivered strong financial performance in 2022, exceeding revenue guidance and positioning for continued growth in 2023 across key business segments.
The company's strategic focus on precision medicine, oncology, and pharma services, coupled with a robust cash position, sets the stage for future expansion and innovation.
Challenges in margin improvement and reimbursement highlight areas for operational refinement, while opportunities in acquisitions and menu expansion offer avenues for sustained growth.

Fulgent Genetics reports robust Q1 revenue growth and strategic advancements

Fulgent Genetics delivered strong revenue growth in Q1 2023, with a focus on core business strength and promising developments in key drug candidates and business segments.
While facing challenges in operational efficiency and negative Adjusted EBITDA, the company maintains a strong cash position and is optimistic about future opportunities.
Strategic acquisitions, market expansion, and continued margin improvement are key areas of focus for Fulgent Genetics to drive sustained growth and profitability.

Fulgent Genetics reports record Q2 revenue and advances in cancer treatment

Fulgent Genetics (FLGT) delivered a strong performance in Q2 2023, with record core revenue and promising developments in cancer treatment.
The company's focus on innovation, operational efficiency, and margin improvement underscores a commitment to sustainable growth.
While facing challenges in cost management and competitive dynamics, Fulgent Genetics is well-positioned to capitalize on opportunities through technology and strategic initiatives.

Fulgent Genetics reports robust Q3 earnings, eyes growth in precision diagnostics

Fulgent Genetics demonstrated solid financial performance in Q3 2023, with strong core revenue and improved gross margins. The company continues to focus on precision diagnostics and therapeutic development, presenting growth opportunities. Challenges include fluctuations in Pharma services revenue and COVID-19 testing demand.

Fulgent Genetics surpasses Q4 revenue targets, eyes FDA regulatory landscape

Fulgent Genetics delivered strong Q4 results, exceeding revenue guidance and showcasing growth in core revenue.
The company faces challenges in BioPharma Services and Anatomic Pathology but is investing in operations and AI for improvement.
Opportunities lie in Precision Diagnostics growth, market share gains in carrier screening, and adapting to FDA oversight of laboratory developed tests.
Management's confidence in quality systems and readiness to pursue FDA approval for high-risk tests position Fulgent Genetics for regulatory changes.

Fulgent Genetics excels in Q1 2024 with strong revenue growth

Fulgent Genetics delivered strong Q1 results driven by precision diagnostics and therapeutic development progress.
While facing challenges in managing expenses, the company showcased financial discipline and innovation in new product launches.
With a focus on improving margins and capturing market opportunities, Fulgent Genetics aims for continued growth and profitability in 2024.

Fulgent Genetics reports robust Q2 revenue, invests in innovative treatments

Fulgent Genetics demonstrated solid revenue performance in Q2, driven by core business growth in key segments.
While facing profitability challenges, the company continues to invest in innovative treatments and technology.
Maintaining a strong cash position and focusing on strategic growth areas position Fulgent Genetics for future success.
Balancing cost management with revenue growth will be crucial for the company's financial health and long-term sustainability.

Fulgent Genetics reports robust Q3 earnings, eyes strategic growth opportunities

Fulgent Genetics demonstrated solid revenue growth and financial stability in Q3 2024.
The company's focus on precision diagnostics and therapeutic development shows promise for future growth.
Challenges lie in maintaining margins, managing expenses, and optimizing the VA contract's impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

23andMe

23andMe is scaling up its pipeline with the help of its collaborators. Fulgent Genetics is rapidly building its oncology testing business.

Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics

BioNTech SE

Certain biotechs that hit it big early during the pandemic are now undervalued. BioNTech is preparing for a rapid pace of new drug launches.

2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that Phase 1/1b clinical data on its lead therapeutic development candidate, FID-007, to treat various solid tumors, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting at 8:00 a.m. Central Time on June 3, 2023 in Chicago, Ill.

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting

We initiate our coverage of Fulgent Genetics with an "outperform" rating and a $42 target price for the next 12 months. The company is continuing its Phase 1 clinical trial evaluating the efficacy of FID-007, a nano-encapsulated paclitaxel, in treating various types of cancer.

What To Expect From Fulgent Genetics In 2023

Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.

Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q1 2023 Earnings Conference Call May 5, 2023 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Dan Leonard - Credit Suisse David Westenberg - Piper Sandler Andrew Cooper - Raymond James Operator Hello and welcome to the Fulgent Genetics Q1 2023 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Fulgent Genetics, Inc. (FLGT) Q1 2023 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to earnings of $4.93 per share a year ago.

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2023. First Quarter 2023 Results: Total Revenue of $66.2 million Core Revenue1 grew 150% year-over-year to $62.7 million GAAP loss of $15.3 million, or $0.52 per share Non-GAAP loss of $6.5 million, or $0.

Fulgent Reports First Quarter 2023 Financial Results

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its first quarter 2023 financial results before the market opens on Friday, May 5, 2023.

Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023

Hackett Group

Malibu Boats

Clearfield

Harmony Biosciences Holdings

Magic Software Enterprises

If you're the type that runs toward danger, these stocks to buy may be right for you. To facilitate mobility, the enterprises on this list feature a market capitalization between $500 million to $2 billion.

7 Stocks to Buy to Bag Big-Time Returns in Q2

Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?

Strategic partnership between Mission Bio and Fulgent Genetics will enable drug developers to leverage single-cell multi-omics for biomarker discovery, clinical research, and single-cell MRD development at scale

Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research

Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

Is Fulgent Genetics (FLGT) Outperforming Other Medical Stocks This Year?

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Tyler Anderson - Piper Sandler Operator Hello, and welcome to the Fulgent Genetics Q4 and Fiscal Year 2022 Earnings Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation.

Fulgent Genetics, Inc. (FLGT) Q4 2022 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.29% and 13.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics, Inc. (FLGT) Reports Q4 Loss, Tops Revenue Estimates

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”, or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Results: Total Revenue of $67.7 million Core Revenue1 grew 97% year-over-year to $55.0 million GAAP loss of $23.8 million, or $0.

Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced the immediate availability of their new Beacon787 expanded carrier screening panel. Beacon787 will include a total of 787 genes associated with autosomal recessive and X-linked conditions.

Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Raymond James & Associates' 44th Annual Institutional Investors Conference on Tuesday, March 7, 2023.

Fulgent to Participate in the Raymond James & Associates' 44th Annual Institutional Investors Conference

Ultra strong balance sheet that has a liquid asset balance almost equivalent to its current market capitalization. Profitable core laboratory testing business even without the temporary COVID-19 windfall.

Fulgent Genetics: Attractive Valuation, But I Prefer To Hold For Now

Today, we revisit Fulgent Genetics. The company continues to manage through a huge drop off in Covid testing revenues as the pandemic ebbs. However, 'core' testing sales are seeing impressive growth and the company has a massive amount of cash on its balance sheet.

Fulgent Genetics: Surviving The Covid Cliff

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Tuesday, February 28, 2023.

Fulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023

San Diego, California--(Newsfile Corp. - January 24, 2023) -  The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Fulgent Genetics, Inc. (NASDAQ: FLGT) shares.Investors who purchased Fulgent Genetics, Inc. (NASDAQ: FLGT) shares prior to 2021 and continue to hold any of their NASDAQ: FLGT shares have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

NOTICE For Investors In NASDAQ: FLGT: Lawsuit Against Fulgent Genetics, Inc. Announced by Shareholders Foundation

NEW YORK--( BUSINESS WIRE )--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, reminds investors of its continued investigation of certain directors and officers of Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ: FLGT) for breaching their fiduciary duties to Fulgent and its shareholders. If you are a Fulgent shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

INVESTIGATION ALERT REMINDER: Scott+Scott Attorneys at Law LLP Investigates Fulgent Genetics, Inc.'s Directors and Officers for Breach of Fiduciary Duties – FLGT

TEMPLE CITY, Calif.--( BUSINESS WIRE )--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Reggie Groves to its board of directors, effective January 3, 2023.

Fulgent Expands Board of Directors with Addition of Reggie Groves

Brookfield Asset Management

dLocal Ltd

Alphabet

Lumentum Holdings

PagSeguro Digital

Molson Coors Brewing

Investors who avoided losing money this year are positioned to consider stocks that are strong conviction buys. An investment idea earns that level of faith when management demonstrates a consistent history of leadership.

News for Fulgent Genetics Stock (FLGT)